Promega, CS3368A22, Filovirus HiBiT-PsVLP Bioassays

Measure the Ability of Antibodies to Neutralize Viral Entry
Neutralizing antibodies, whether generated through vaccination or produced as therapeutic monoclonal antibodies, are critical for stopping acute and chronic viral infections. Filoviruses like Ebola and Marburg are important targets for researchers developing vaccines, prophylactic monoclonal antibodies or small-molecule inhibitors. Researchers need to determine the neutralizing capacity of their therapeutic, but current methods like PRNT or PNA require infection-competent virus, stringent biosafety measures and cannot be readily implemented in most laboratories.
There are several HiBiT-PsVLP Bioassays designed for Filoviruses that utilize NPC1 for host cell entry. They provide a simple, easily implemented and robust system that can be used to measure the viral neutralization activity of both antibody and small-molecule inhibitors that block viral entry into target cells. The assay consists of a PsVLP from the Filovirus family, such as Ebola or Marburg virus, and a target cell line expressing NPC1. The PsVLP and Target Cell each contain one piece of a split luciferase technology to provide a low-background and convenient luminescent readout.